Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma Meeting Abstract
| Authors: | Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Hernandez-Ilizaliturri, F.; Horwitz, S.; Intlekofer, A. M.; Johnson, W. T.; Karmali, R.; Lue, J. K.; Kumar, A.; Luttwak, E.; Mahajan, N.; Marouf, A.; Noy, A.; Owens, C.; Palomba, M. L.; Salles, G.; Schoder, H.; Sermer, D.; Seshan, V.; Steiner, R. E.; Torka, P.; Zelenetz, A. D.; von Keudell, G.; Moskowitz, A. |
| Abstract Title: | Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 3053 |
| End Page: | 3055 |
| Language: | English |
| ACCESSION: | WOS:001412786000001 |
| DOI: | 10.1182/blood-2024-210053 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Hybrid event -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
